Status: Recruiting
Novel Therapies for Severe Acute GVHD (Graft-versus-host Disease)
The purpose of this study is to determine the efficacy and safety of combined Ruxolitinib With Corticosteroids as First Line Therapy for the severe acute GVHD (graft-versus-host disease )
Participants needed: 54
Trial details
Phase: Phase 2Age: 14+Biological sex: AllType: InterventionalSponsor: Daihong LiuUpdated: Apr 3, 2026Locations: 1
Eligibility criteria
diagnosed with hematological diseases. [+2]
Recipients of second allogeneic stem cell transplant. [+11]